Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?

Lignende værker

• Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
  af: Kristensen, Lars Erik, et al.
  Udgivet: (2018)
• The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice
  af: K. V. Sakharova, et al.
  Udgivet: (2020-11-01)
• Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
  af: Liu, Yifei, et al.
  Udgivet: (2019)
• The Law and Ethics of Switching from Biologic to Biosimilar in Canada
  af: Murdoch, Blake, et al.
  Udgivet: (2020)
• Biologics and biosimilars: what, why and how?
  af: Chan, Juliana CN, et al.
  Udgivet: (2017)